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Mihaela Škulj1*, Dejan Pezdirec1, Dominik Gaser1, Marko Kreft2,3,4 and Robert Zorec2,3Abstract
Background: During development of recombinant monoclonal antibodies in Chinese hamster ovary (CHO) cells,
C-terminal amidated species are observed. C-terminal amidation is catalysed by peptidylglycine α-amidating
monooxygenase (PAM), an enzyme known to be expressed in CHO cells. The significant variations between clones
during clone selection, and the relatively high content of amidated species (up to 15%) in comparison to reference
material (4%), led us to develop a cell line with reduced production of C-terminal amidated monoclonal antibodies
using genetic manipulation.
Results: Initial target validation was performed using the RNA interference approach against PAM, which resulted in
a CHO cell line with C-terminal amidation decreased to 3%. Due to the transient effects of small-interfering RNAs,
and possible stability problems using short-hairpin RNAs, we knocked-down the PAM gene using zinc finger
nucleases. Plasmid DNA and mRNA for zinc finger nucleases were used to generate a PAM knock-out, which
resulted in two CHO cell lines with C-terminal amidation decreased to 6%, in CHO Der2 and CHO Der3 cells.
Conclusion: Two genetically modified cell lines were generated using a zinc finger nuclease approach to decrease
C-terminal amidation on recombinant monoclonal antibodies. These two cell lines now represent a pool from
which the candidate clone with the highest comparability to the reference molecule can be selected, for production of
high-quality and safe therapeutics.
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The production of biopharmaceuticals for human use
began in 1982 with recombinant insulin, and the devel-
opment of new biopharmaceuticals has grew almost
exponentially ever since. Over the past two decades,
Chinese hamster ovary (CHO) cells have become the
standard mammalian host cell line, with the expression
and production of nearly 70% of all biopharmaceuticals
[1,2]. CHO cells provide efficient post-translational mod-
ifications, which allow the production of recombinant
proteins with glycoforms that are both compatible with,
and bioactive in humans [1]. CHO cells can also be eas-
ily manipulated genetically, which has become of great
importance more recently [3]. These two characteristics* Correspondence: mihaela-1.skulj@sandoz.com
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unless otherwise stated.are especially important in the production of biosimilars,
where achieving the correct extent of similarity to the
reference molecule is a great challenge. The nucleotide
sequence of the gene that encodes amino-acid sequence
of the desired protein is the same as for the reference
molecule. In contrast, post-translational modifications
that are the consequence of metabolic pathways can dif-
fer between host cell lines, clones, cultivation conditions,
medium composition, specific productivity and physio-
logic state of the cell [4]. Consequently, these need to be
fine-tuned during development. In addition to posttrans-
lational modifications, different charge variants can re-
sult in heterogeneity in the production of monoclonal
antibodies (mAbs). These modifications potentially re-
sult in changes to the bioactivity, bioavailability or im-
munogenicity of the mAbs, and they therefore need to
be additionally characterised to ensure the safety, quality
and efficacy of the product. Among these, C-terminald. This is an Open Access article distributed under the terms of the Creative
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recently attracted particular attention [5-8].
C-terminal α-amidation is catalysed by peptidylglycine
α-amidating monooxygenase (PAM), and this protein
modification is often required to confer full biological
activity to peptide hormones [6,9-11]. Amidation is cata-
lysed starting from a glycine-extended prohormone, by
two sequential actions of two enzymes, peptidylglycine
α-hydroxylating monooxygenase and peptydilamido-
glycolat lyase. In mammals, both of these enzymes are
derived from a single gene, which gives rise to the bi-
functional PAM protein [12]. PAM thus catalyses the
conversion of peptidylglycine substrates into α-amidated
products in a two-step reaction, and it is the only en-
zyme known to catalyse the formation of amidated pep-
tides [13].
Recently, large proteins like immunoglobulins have
been reported to be substrates for PAM [6,7], and the
expression of PAM in CHO cells was reported previ-
ously [14]. Tsubaki et al. reported that C-terminal α-
amidation was detected in 8 of 12 recombinant mAbs,
with ratios from 0.3% to 25.9% [6]. During our studies,
we have also observed the presence of C-terminal ami-
dated species in recombinant mAbs produced in CHO
cells. Prolinamide was detected in up to 14% of all mAb
molecules, which was too high to accomplish the desired
similarity to the reference molecule.
It was previously shown that the level of mAb amida-
tion in CHO cells can be affected via bioprocesses and
medium optimisation, with the addition of copper to the
culture medium [7]. On the other hand, metabolic en-
gineering is becoming a powerful tool to manipulate ex-
pression hosts for improved product quality, and the
introduction of a PAM knocked-down cell line that can
produce mAbs with desired comparability to a reference
molecule would be a state-of-the-art solution.
In the present study, the expression of PAM, and con-
sequently the C-terminal amidation of recombinant
mAbs, was reduced by two approaches: gene manipula-
tion using RNA interference (RNAi) and zinc finger
nucleases (ZFN). RNAi has been efficiently used for
down-regulation of desired genes, and it can be per-
formed using chemically synthesised small-interfering
(si)RNA molecules, or via the endogenous expression of
short-hairpin (sh)RNA molecules that are encoded by
plasmid vectors [15,16]. While siRNAs can provide tran-
sient knock-down of expression of a target gene, shRNA
vectors can induce long-term expression of RNAi silen-
cing in a target cell [15]. The ease and rapidity of these
RNAi approaches have made them the method of choice
for initial target validation.
However, using RNAi, complete elimination of expres-
sion of the target gene is rarely obtained. To achieve
permanent gene knock-out, ZFNs can offer a distinctadvantage. Moreover, the growing number of reports
using ZFNs across different species suggests that ZFN-
mediated gene disruption is a robust and general
method for targeted gene knock-out. As this approach
results in an alteration of the genome itself, these muta-
tions are transmitted stably through all of the subse-
quent generations of the cell line, as is the case with
conventional gene targeting [3,17]. Rapid gene knock-
out can be achieved by using a ZFN approach to create
a double-stranded break in the locus of interest, which
allows it to be repaired by non-homologous end-joining;
this ligates the two broken ends, with the occasional loss
of genetic information. ZFNs can therefore be used to
introduce small deletions at the site of such a break, an
outcome that can be exploited to disrupt a target gene
[18,19]. The high frequencies of gene disruption strongly
support the likelihood of achieving a desired genotype,
in which each copy of the target gene is functionally
knocked out in 1% to 50% of all cells [17,18].
Results and discussion
siRNA and shRNA experiments
C-terminal amidation is a common posttranslational
modification that is seen on therapeutic mAbs [6], and
which has also been observed during recombinant mAb
development (data not shown). The significant variations
between clones during clone selection, and the relatively
high content of amidated species in comparison to refer-
ence molecules, directed us towards the development of
a cell line with reduced production of C-terminal ami-
dated species.
RNAi has already been efficiently used for the im-
provement of cellular productivity and the quality of re-
combinant proteins produced in CHO cells. RNAi had
thus been used for silencing apoptosis-associated gene
expression [20-23], glycosylation-associated gene expres-
sion [24-26], and gene expression of lactate dehydrogen-
ase [27] and dihydrofolate reductase [28,29].
Fifteen different siRNAs were designed on the basis of
the C. griseus PAM nucleotide sequence and tested on
the CHO Der2 parental cell line. Up to an 8-fold de-
crease was observed in PAM mRNA expression levels
using siRNAs from Invitrogen, and up to a 5-fold de-
crease using siRNAs from Ambion (Figure 1). On the
basis of these data, and due to shRNA design limitations,
siRNAs si5 and si6 (Ambion) were selected for the de-
sign of shRNAs, to obtain long-term silencing of PAM.
siRNA knock-down of the target lasts for 3 to 5 days,
and therefore to induce long-term expression of RNAi
silencing in the target cells, an shRNA vector has to be
used [15]. The shRNA silencing effect was tested on two
different CHO parental cell lines, CHO Der2 and CHO
Der3, and on two mAb-expressing clones derived from
the CHO Der3 cell line, clone K62 with high (14%), and
Figure 1 Silencing of PAM using siRNA. PAM mRNA expression
level after transfections using the siRNAs (Invitrogen, Ambion, as
indicated) in the CHO Der2 parental cell line. In comparison to the
negative control (−K), there was up to 8-fold reduction in the mRNA
expression levels using the si6 Invitrogen siRNA, and up to 5-fold
reductions using the si5 and si6 Ambion siRNAs. Overall, better
silencing effects were obtained using the Invitrogen siRNAs. The
mRNA expression levels were determined using qPCR (calculated
per ACTB housekeeping gene), and the data are means ± standard
deviations of the two biological replicates.
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mAb that was produced (Figure 2). After shRNA trans-
fection and antibiotic selection, all of the generated
pools were analysed by cation-exchange chromatography
(CEX), for evaluation of the prolinamide content
(Figure 2). The shRNA designed on the basis of the si6
siRNA was shown to have the most potent silencing ef-
fect on all of the transfected cell lines (Figure 2).Figure 2 Silencing of PAM using shRNA. The mRNA expression levels are
on the CHO Der2 and CHO Der3 parental cell lines and on the K25 and K62
obtained for the parental cell lines are in grey. In comparison to the negat
effects were achieved with shRNA sh6 and 5 μg/ml antibiotic selection (5 μg
levels was seen for the CHO Der2 cell line, and up to 2.6-fold reduction for th
K62 are in black. In this case, the PAM expression level and the prolinamide co
and K62 -K), the different antibiotic selections did not show any differences in
reduction in mRNA expression levels was observed for K25, and up to 2.2-fold
and from 14% to 4.6% for K62, which represents a 3-fold decrease. The mRNA
determined using qPCR (calculated per ACTB housekeeping gene), and the daThe data presented in Figure 2 show the correlation
between PAM mRNA expression levels and C-terminal
amidation of the recombinant mAb. Up to a 4-fold de-
crease in mRNA and a 3-fold decrease in prolinamide
content were observed. As can be seen from Figure 2,
the prolinamide content for clone K62 was decreased to
4.6%, which represents a 3-fold decrease, and for clone
K25, where the initial starting point was 3.5% prolina-
mide content, only a minimal reduction was obtained.
Nevertheless, there is an interesting observation here
that should be considered. No matter which clone is
considered, as one with a previously high (14%) or low
(4%) prolinamide content, the reduction in the prolina-
mide content after shRNA knock-down never decreased
below 4%, which is the same as the level of the reference
molecule.
ZFN experiments
The shRNA experiments gave very promising results, as
they yielded PAM levels that were comparable to the ref-
erence molecule. However, possible toxicity effects on
long-term expression and the additional metabolic load
on the cells due to the overexpression of these factors
during times of stress might also influence cell perform-
ance. In addition, shRNA-mediated knock-down relies
on the constant expression of repressor molecules,
which can be unstable in the knocked-down cells in the
long term [17]. RNAi instability was reported by Lim
et al. in the silencing of the BAX and BAK genes, where
1% of the screened clones was silenced for both genes,shown after the transfections using the Ambion sh5 and sh6 shRNAs
clones derived from the CHO Der3 parental cell line. The data
ive controls (CHO Der2 -K, and CHO Der3 -K), the highest silencing
puromycin [PURO]). Up to 3.7-fold reduction in the mRNA expression
e CHO Der3 cell line. The data for the mAb-expressing clones K25 and
ntent (%) are presented. In comparison to the negative controls (K25 -K,
mRNA expression levels and prolinamide content. Up to 3.5-fold
reduction in K62. Prolinamide was decreased from 3.5% to 3% for K25,
expression levels for parental cell lines and the K25 and K62 clones were
ta are means ± standard deviations of two biological replicates.
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clones [20]. This is an undesirable feature during the
mAb production process, as it can cause heterogeneity
of the product [20]. To avoid such problems, rapid and
permanent gene knock-out using ZFNs can offer distinct
advantages. Moreover, the growing number of reports
using ZFNs across different species have suggested that
ZFN-mediated gene disruption is a robust and general
method for targeted gene knock-out. ZFN-mediated
gene knock-out requires only transient expression of the
ZFNs, and it can result in a permanent genetic mutation
that is stably transmitted through all of the subsequent
generations of the cell line [17].
The first reported example of the use of engineered
ZFNs to disrupt an endogenous locus in a mammalian
cell was a knock-out of the dihydrofolate reductase gene
in CHO cells. The observed bi-allelic mutation rate was
2% to 3%. In comparison to traditional methods, this fre-
quency of gene disruption is very high, and it increases
the possibility of achieving the desired genotype in
which each copy of the target gene is functionally
knocked out [17].
ZFNs have also already been successfully used for the
generation of many different knocked-out CHO cell
lines. They have been reported as used to create triple
knock-out CHO cells, with the disruption of the two
selectable marker genes of glutamine synthetase and
dihydrofolate reductase, as well as the gene encoding α-
1,6-fucosyltransferase (FUT8) [30]. BAK and BAX dele-
tion was also achieved, to produce apoptosis-resistant
CHO cells [31]. Additionally a FUT8 knock-out CHO
cell line has been reported [32,33].
Thus, ZFNs were used to create a cell line with stably
knocked-down PAM expression, so as to reduce C-
terminal amidated species on the target mAb. These
ZFNs were designed on the basis of a sequence that had
been shown to generate silencing effects using RNAi.
Initially, ZFN plasmid DNA was used for the transfec-
tions of the parental CHO Der2 and CHO Der3 cell
lines. The knock-out effect was evaluated by determin-
ation of the PAM gene copy number using qPCR. This
method was evaluated using the Cell-I Nuclease Mis-
match assay (data not shown), which is usually used to
evaluate knock-out clones. The qPCR method has been
shown to be less laborious and time consuming, and
therefore it enables efficient screening of the high num-
bers of clones generated.
In all, 85 clones were generated from the CHO Der2
cell line, and 109 clones from the CHO Der3 cell line. In
contrast to the CHO Der2 cell line, which is diploid, the
CHO Der3 cell line was shown by karyotyping to be a
triploid (data not shown), and a knock-out was therefore
more difficult to achieve. A partial reduction of the PAM
copies in the CHO Der2 and CHO Der3 cell lines wasachieved (Figure 3). Reported knock-out efficiencies for
single copy genes have been higher than 1% [17,30,34],
and have reached 5% [33]. Thus, to detect a single clone
with a total knock-out that would be reflected in a mAb
without functional PAM, around 100 clones would need
to be generated, and in the case of the triploid CHO
Der3 cell line, this would be higher.
The PAM mRNA expression was evaluated for the 10
best clones by qPCR, and high correlation was observed
with the copy number determination at the genomic
DNA level (data not shown).
To determine the mRNA expression levels, the PAM
mRNA was calculated per housekeeping gene. The
choice of a housekeeping gene can often be quite chal-
lenging, as expression is usually not the same across dif-
ferent CHO cell lines and clones, and can also vary
according to the physiological state of the cells. To avoid
these effects, four different housekeeping genes were
tested in the present study: ACTB, GAPDH, G6PD and
EF1 (Table 1). All four of these housekeeping genes were
shown to be suitable for the calculation of the mRNA
expression levels (data not shown), with the data below
are based on the use of ACTB as the housekeeping gene.
The three best clones were transfected with a plasmid
containing the mAb expression cassette. After 4 weeks
of antibiotic selection and 14 days of fed-batch cultiva-
tion, the mAbs produced from these three clones were
evaluated for the presence of prolinamide, using CEX.
The data from the PAM gene copy numbers, mRNA ex-
pression levels, and prolinamide content are presented
in Figure 4. The prolinamide levels for both of the CHO
Der2 and CHO Der3 cell lines after evaluation using
CEX were determined to have decreased to 6%. As ob-
served with the shRNA (see above), there was correl-
ation between copy number, mRNA expression, and
prolinamide content of the recombinant mAb (Figure 4).
Transfections using ZFN plasmid DNA result in its
random integration into the genome of CHO cells and
continuous expression of the ZFN. Genome integration
is not desired, due to the continuous ZFN activity, and
thus potential off-target effects. The mechanism of ZFN
target recognition has been reported to be highly spe-
cific, with usually an 18-bp site recognized and the
dimerisation of two ZFNs needed to cause a double-
stranded break [18,35]. Despite this, some off-target ef-
fects have also been observed. Off-target effects of 5.4%
were reported for the disruption of the CCR5 HIV re-
ceptor by Klug et al. [19].
To avoid this, the transfections were performed using
ZFN mRNA, for transient ZFN expression. The ZFN
mRNA was prepared in-house using in-vitro transcrip-
tion from the two ZFN plasmid DNAs. The cells were
then transfected with the two ZFN mRNAs; i.e., ZFN1
and ZFN2. Various amounts for the combination of
Figure 3 PAM gene copy numbers for the clones derived from the CHO Der2 and CHO Der3 cell lines transfected using the ZFN
plasmid DNA. The PAM gene copy numbers for the 85 ZFN clones derived from the CHO Der2 parental cells (a) and the 109 ZFN clones derived
from the CHO Der3 parental cells (b), transfected using the ZFN plasmid DNA. The copy numbers were determined using qPCR, and the data are
means ± standard deviations of two technical replicates.
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60 μg per transfection. The 50 μg mRNAs transfection
(25 μg ZFN1 mRNA, 25 μg ZFN2 mRNA) was the most
promising combination. The concentrations of the
mRNAs used for the transfections correlated with the si-
lencing effects, although the higher mRNA concentra-
tions decreased the cell viability to <80% (data not
shown). The pools were evaluated by qPCR on day 4 fol-
lowing transfection. A 50% knock-out was achieved for
the generated pools, and the cell viability was >80%,
which is needed for seeding into the semi-solid medium
for clone generation using ClonePix.
These mRNA transfections were used only with the
CHO Der2 cell line. Here, 154 clones were evaluated







PAM, peptidylglycine amidating monooxygenase; ACTB, β-actin; GAPDH, glyceralde
Glucose-6-phosphate dehydrogenase.at the genomic DNA level by qPCR (Figure 5), which
represented a 1% knock-out efficiency. The 10 best
clones were again tested for PAM mRNA expression
(data not shown), and afterwards the best three of these
10 clones were transfected with a plasmid containing the
mAb expression cassette, in duplicates, and evaluated by
CEX (using the same procedure as described for the
plasmid DNA transfections). These data are presented in
Figure 6.
The C-terminal amidated structures in all of these
tested clones decreased to a limit of 6%, which was the
same as observed using ZFN plasmid DNA. mRNA ex-
pression and C-terminal amidation were observed for all
of these tested clones, even though this was not ex-







hyde-3-phosphate dehydrogenase; EF1, elongation factor 1; G6PD,
Figure 4 PAM gene copy numbers, mRNA expression and C-terminal amidation for clones transfected using ZFN pDNA. The PAM gene
copy numbers (a), PAM mRNA expression levels (b; calculated per ACTB housekeeping gene), and prolinamide content on the recombinant mAb
(c) for the three best ZFN knock-out clones derived from the CHO Der2 and CHO Der3 parental cell lines, where ZFN pDNA was used for the
transfection. Prolinamide was reduced to 6%. The copy numbers and mRNA expression levels were determined using qPCR, and the data are
means ± standard deviations of two technical replicates. The prolinamide content was determined using CEX, and these data are means ± standard
deviations of two biological replicates.
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on cell growth, in comparison to the non-silenced con-
trols. All of the cells showed similar cell growth, which
did not differ from that expected for CHO cells. Add-
itionally, there was no correlation between cell product-
ivity and C-terminal amidation of the produced mAb
(data not shown).
The silencing effects that were obtained using the
RNAi approach showed more promising results in terms
of prolinamide reduction on the recombinant mAb. In
this case, prolinamide was reduced to 3%. As indicated
above, siRNA effects are only transient [15] and the
shRNA approach is also questionable, due to long-term
stability problems and the additional metabolic burden on
the cells. Using the ZFN approach, the decrease in proli-
namide was not as effective as with shRNA, as it was re-
duced to 6%. On the other hand, this ZFN approach has
the advantage of producing a stable genetic modification,
which is very important for the production scale.
After transfection with the mAb-expressing plasmid,
each of these two generated ZFN knocked-down cellFigure 5 PAM gene copy numbers for 154 ZFN clones from CHO Der2
(K62 and K68) identified as knocked-out for all PAM gene copies at the gen
data are means ± standard deviations of two technical replicates.lines (CHO Der2 and CHO Der3 cells) represented a
mixed cell population with a mean prolinamide content
of 6%. In comparison to the negative controls, which
generated 15% (CHO Der2) and 14% (CHO Der3)
prolinamide content, this represents a decrease in the
prolinamide content of >50%. These pools with mean
prolinamide content of 6% thus represent good starting
points for the isolation of candidate clones that express
different amounts of C-terminal amidated species, thus
providing the choice for the one that is the most com-
parable to the reference molecule.
The higher efficiency of the knock-down achieved
using shRNA in comparison to ZFN might be because
the shRNA targets the degradation of the PAM mRNA,
which will reduce its expression overall. For the ZFNs,
the knock-out effects are at the level of the genomic
DNA, and if total knock-out is not achieved in all of the
copies, the expression of a functional mRNA will still
take place, and thus the translation into the functional
PAM protein will not be fully blocked. Disruption of the
target gene can occur by causing a shift in the readingparental cell line transfected using ZFN mRNA. The two clones
omic DNA level. The copy number was determined by qPCR, and the
Figure 6 PAM gene copy numbers, mRNA expression, and C-terminal amidation for the clones transfected using ZFN mRNA. The PAM
gene copy numbers (a), PAM mRNA expression levels (b; calculated per ACTB housekeeping gene), and prolinamide contents of the recombinant
mAb determined by CEX (c), for the three best ZFN knock-out clones derived from the CHO Der2 parental cell line, where ZFN mRNA was used
for the transfection. The two clones identified (K62 and K68) were knocked-out for all PAM gene copies at the genomic DNA level, with mRNA
expression and a prolinamide content of 6% still observed. The copy numbers and the mRNA expression levels were determined using qPCR, and
the data are means ± standard deviations of two technical replicates. Prolinamide content was determined by CEX, results are presented as an
average of two biological replicates.
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or the deletion of critical amino-acid residues. However,
the result of non-homologous end joining repair might
be only an amino-acid point mutation or a deletion of
the protein molecule, which might result in a partially or
fully functional enzyme.
However, the goal of the present study was not to gen-
erate a completely knocked-out CHO cell line, but to
decrease the content of the C-terminal amidated struc-
tures to a level that is sufficiently comparable to the ref-
erence molecule, and this was successfully achieved
using both approaches.
Conclusions
During development, C-terminal amidated species are
detected on recombinant mAbs, an observation that was
also recently reported in other studies [6]. C-terminal
amidation can be reduced by development and optimisa-
tion of the grwth medium, and use of cofactors such as
copper [7], although these approaches are project spe-
cific and time consuming. Due to its extensive develop-
ment, metabolic engineering has provided a powerful
tool to diminish the expression of the PAM gene
through gene alterations using RNAi and ZFNs. In the
present study, both of these approaches were tested. The
RNAi was conducted for the initial target validation, for
the later ZFN knock-out. Using the shRNA approach,
decreases in C-terminal amidation were achieved for
two mAb-producing clones: the K25 with low prolina-
mide content (4%), and the K62 clone with high (14%)
prolinamide content, which were decreased to 3.5% and
5%, respectively. The prolinamide levels of the reference
molecule were 4%, and therefore a comparability level
was successfully achieved. In this case, the gene silencing
was performed on two clones that were already express-
ing the desired mAb.For recombinant mAb production, a parental cell line
with stably reduced PAM expression is desired. To
achieve this, genome alterations using ZFNs are the
more appropriate tool, as breaks are created at the gen-
omic DNA level that are stably transferred through the
subsequent generations of the cell line [3,17]. Two CHO
cell lines were generated, as CHO Der2 and CHO Der3
cells, and they were evaluated for PAM at the genomic
DNA and mRNA expression levels. After the selection
of the three most promising clones, these were trans-
fected with a mAb-producing plasmid and evaluated for
the C-terminal amidated species. The C-terminal amida-
tion was decreased to 6% in both of these cell lines,
which represents a 50% lower content in comparison to
the ZFN non-treated controls. The two generated cell
lines now represent two pools from which candidate
clones with the highest comparability to the reference
molecule can be selected.
Thus, this use of genetically manipulated cell lines
now gives us the opportunity to go even further towards
providing high-quality and safe therapeutics.
Methods
Design of siRNAs, shRNAs and ZFNs
The Chinese hamster (Cricetulus griseus) PAM nucleotide
sequence was derived from a public database (Table 2).
The siRNAs, shRNAs and ZFNs were constructed on the
basis of this sequence.
The online design tools of Invitrogen and Ambion
were used to design the siRNA sequences (nine accord-
ing to Invitrogen, six according to Ambion; Table 3).
After the siRNA evaluation, shRNAs were designed
using the Ambion online design tool. Two complemen-
tary oligonucleotides were synthesised for each shRNA
by Methabion (Table 4), and then these were annealed in-
house, to generate the double-stranded oligonucleotides.











Škulj et al. BMC Biotechnology 2014, 14:76 Page 8 of 11
http://www.biomedcentral.com/1472-6750/14/76Subsequently, these annealed oligonucleotides were cloned
into the pSilencer 2.1-U6 puro vector (Ambion). DNA se-
quencing was performed to verify the sequences of the
oligonucleotide inserts.
For the ZFN experiments, two ZFN plasmids that tar-
geted the PAM gene (pZFN PAM1, pZFN PAM2) were
designed by Sigma (CompoZrTM Custom Zinc Finger
Nuclease, PN. SAFCZFN-1kt). These two ZFN plasmids
were later used as templates for the preparation of
PAM1 and PAM2 mRNA, by in-vitro transcription using
MessageMax T7 ARCA-Capped Transcription Kit (Cell-
script). The transcripts were poly-A tailed using A-Plus
Poly(A) Polymerase Tailing Kit (Cellscript), and purified
using RNeasy Micro Kit (Qiagen). The RNA concentra-
tions were determined by the NanoDrop, and the tran-
script sizes were evaluated using a Bioanalyser.
Cell culture and transfection
siRNA and shRNA experiments
Two different CHO parental cell lines (CHO Der2 and
CHO Der3) and two different mAb-producing clones
that were derived from the CHO Der3 cell line (clone
K25 and clone K62) were used in this study. Clones K25Table 3 Nucleotide sequences of the siRNAs used in the
present study















siRNA_si6 UUUCAGAACUGACACCAAATT Ambionand K62 were prepared by nucleofection of the parental
CHO Der3 cell line using a plasmid vector containing
the mAb expression cassette. The cells were cultivated
at 37°C, under 10% CO2, and with agitation at 90–
110 rpm, in animal-component-free growth medium.
The C-terminal amidation of the mAb in clone K25 was
determined as 4%, and in clone K62, as 14%, using CEX.
It was shown that 4% of all of the reference molecules
contained C-terminal amidated structures.
For the siRNA experiments, CHO Der2 cells were
transfected with siRNAs, in duplicate, using nucleofec-
tion, and cultivated for 4 days. On day 4, the cell pellets
were collected for analysis of gene expression by qPCR.
For the shRNA experiments, all four cell lines (CHO
Der2, CHO Der3, clone K25, and clone K62) were trans-
fected with shRNAs, in duplicate, using nucleofection.
Antibiotic selection of all of the transfected pools was
performed using 3 μg/ml puromycin. The puromycin
was added to the cell culture 2 days after the transfec-
tion, when the cell viability exceeded 60%. The cells
were split on a 2-2-3-day schedule at 2-3E5 cells per ml,
in the appropriate pre-warmed medium to maintain ex-
ponential cell growth. After reaching the appropriate cell
density and viability, the cell pellets were collected for
gene expression analysis by qPCR, and a 10-day simple
batch containing 3 μg/ml puromycin was inoculated
(after 10 days, the supernatants were collected, purified
on protein A columns, and evaluated for prolinamide
content using CEX). The cells were further cultivated in
medium containing 5 μg/ml puromycin. After reaching
the appropriate cell density and viability, this procedure
was repeated.
ZFN experiments
For the ZFN experiments, the CHO Der2 and CHO
Der3 parental cell lines were transfected using 3 μg of
each ZFN plasmid (PAM1, PAM2), by nucleofection.
After 4 days, the cells were seeded into the semi-solid
medium, and on day 10 the colonies were transferred
into 96-well plates by ClonePix FL. After colony forma-
tion in the 96-well plates, the individual colonies were
transferred into 24-well plates, and later into 6-well
plates. Finally, the clones were transferred into 125-ml
shaking flasks, and after achieving the appropriate cell
density and viability, the cell pellets were collected for
Table 4 Nucleotide sequences of the shRNAs used in the present study
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pression by qPCR. The same procedure was repeated on
the CHO Der2 cell line using 25 μg of each ZFN mRNA
(PAM1, PAM2), which was prepared in-house from the
PAM1 and PAM2 ZFN plasmids.
After the selection of the three clones with the highest
knock-down efficiency generated using ZFN plasmid
DNA and mRNA, the transfections were performed
using 3 μg mAb-expressing vector, in duplicate. After
4 weeks of antibiotic selection with geneticin, a 14-day
fed-batch was inoculated. After 14 days, the supernatants
were collected and purified using protein A columns. The
prolinamide contents were evaluated using CEX.
DNA/RNA purification and qPCR template preparation
The genomic DNA and the total RNA were isolated
from pellets containing 5E6 cells on an automated QIA-
cube workstation. The genomic DNA was isolated using
Blood & Cell Culture DNA Mini Kit (Qiagen), and the
total RNA using RNeasy Mini Kit (Qiagen). After isola-
tion, the nucleic acid concentrations were measured
using the NanoDrop. After the determination of the
total RNA concentrations, DNase I (Ambion) was added
to 5 μg total RNA and incubated according to the manu-
facturer instructions. After this DNase treatment, the
RNA was transcribed into cDNA using SuperScript VILO
Kit (Invitrogen).
The genomic DNA and cDNA were used later as tem-
plates for the qPCR. The cDNA was used for evaluation
of the siRNA and shRNA silencing effects, while the
genomic DNA was used for evaluation of the knock-out
effects of clones produced using the ZFNs.
qPCR experiments
siRNA and shRNA experiments
The silencing effects of the siRNAs and shRNAs were
examined by qPCR, using TaqMan chemistry and abso-
lute quantification. The standard curve was constructed
from CHO Der1 genomic DNA, which was amplified
using the PAM and ACTB primers (Table 1). The PAM




GLUC, glucagon; PAM, peptidylglycine amidating monooxygenase.extrapolated from the standard curve, and the PAM
mRNA expression levels were expressed as the number
of PAM mRNA transcripts per reference ACTB gene.
The standard curves were constructed from five dilution
points, each as three parallel determinations. The PAM
mRNA expression levels were determined as four dilu-
tion points, each as two parallel determinations for each
sample.
ZFN experiments
The efficiencies of the ZFNs were determined by qPCR,
using TaqMan chemistry and absolute quantification.
The TaqMan probe was designed on the ZFN cutting
site, and therefore no amplification of the PAM gene
was expected in completely knocked-out clones. The
standard curve was constructed from the CHO Der1
genomic DNA amplified using the GLUC and PAM
primers (Table 5). The copy numbers for both of these
genes were extrapolated from the standard curve for
each sample, and the ratio between them was calculated.
GLUC is a single-copy gene in CHO cells, and was used
as the reference gene for the PAM gene copy number
determination. Standard curves were constructed from
five dilution points, each as three parallel determina-
tions. The PAM copy numbers were determined as two
dilution points, each as three parallel determinations for
each sample.
After the selection of the 10 clones with the highest
knock-out efficiency, the PAM expression was determined
as described above, using four different housekeeping
genes: GAPDH, ACTB, G6PD and EF1 (Table 1).
Cation-exchange chromatography
The mAb concentrations were determined using the
ForteBio system. The mAbs were purified using protein
A columns and analysed using CEX, with an analytical
HPLC chromatographic system. Using this method, Lys
and prolinamide were eluted in the same peak. The
amount of prolinamide was then determined by C-
terminus treatment with carboxypeptidase. Following
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linamide levels are given as percentages of the C-
terminal amidated species of the total mAb content.
After carboxipeptidase treatment, in addition to proli-
namide, the basic peak can include multiple species, like
N-terminal cyclised species, succinimide species, hybrid
glycan-containing species, and others. Therefore the
CEX analysis was always performed in parallel with the
non-silenced and non-knockout controls, represented by
samples from the same cell lines that had undergone
blank transfections and were grown under the same con-
ditions. The effects of RNAi and the ZFNs on the treated
samples are highly specific, and the probability of other
post-translational modifications other than reductions in
prolinamide is very low. The reductions in the C-terminal
amidation were determined relative to the controls, and
therefore the reduction in the basic peak defined the re-
duction in C-terminal amidation.
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